According to a new report, published by KBV research, The Global Human Milk Oligosaccharides Market size is expected to reach $1 billion by 2030, rising at a market growth of 23.3% CAGR during the forecast period.
The Infant Formula segment is growing at a CAGR of 22.8 % during the forecast period. One of the primary reasons for incorporating HMOs into infant formula is to mimic the nutritional composition of human breast milk more closely. HMOs are complex carbohydrates that serve as prebiotics, supporting the maturation of beneficial bacteria in the infant's gut. When added to infant formula, HMOs are generally well-tolerated and considered safe for consumption. Studies have shown that these compounds pass through the digestive system without being absorbed, reaching the colon, where they exert their prebiotic effects.
The 2'FL segment is generating the maximum revenue in the Global Human Milk Oligosaccharides Market, by Type in 2022; thereby, achieving a market value of $571 Million by 2030. One of the primary roles of 2'FL is to act as a prebiotic. Prebiotics are non-digestible compounds that promote the development and movement of healthy bacteria in the gut. In the case of 2'FL, it selectively nourishes certain strains of Bifidobacteria, which are considered beneficial for gut health. 2'FL has received regulatory approval for use in infant formula products in several countries. Regulatory bodies have assessed its safety and nutritional suitability, providing a framework for its inclusion in commercial products.
The Neutral segment is registering a CAGR of 22.9 % during the forecast period. The most prevalent form of HMOs discovered in breast milk functions as an energy provider for the infant while also fostering the development of advantageous gut flora. These lack acidic residues and are not linked to sialic acid. Most of the common HMOs, like lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and 2'-fucosyllactose (2'-FL), fall into the category of neutral HMOs. These neutral HMOs often function as prebiotics, promoting the growth of beneficial bacteria in the infant's gut and supporting the development of healthy microbiota.
The Asia Pacific region dominated the Global Human Milk Oligosaccharides Market, by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $486 Million by 2030. The Europe region is anticipated to grow at a CAGR of 22.4% during (2023 - 2030). Additionally, The North America region would witness a CAGR of 23% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/human-milk-oligosaccharides-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Koninklijke DSM N.V., BASF SE, Chr. Hansen Holding A/S, DuPont de Nemours, Inc., Nestle S.A, Inbiose NV, Biosynth AG, Abbott Laboratories, Royal FrieslandCampina N.V. and Dextra Laboratories Ltd (ICE S.p.A)
By Application
By Type
By Concentration
By Geography
Companies Profiled
Unique Offerings 
